Entera Net Cash Flow from Operations Trend from 2010 to 2022

ENTX
 Stock
  

USD 1.88  0.10  5.62%   

Entera Bio Net Cash Flow from Operations yearly trend continues to be fairly stable with very little volatility. Net Cash Flow from Operations will likely drop to -9,778,500 in 2022. . Entera Bio Operating Expenses is fairly stable at the moment as compared to the past year. Entera Bio reported Operating Expenses of 12.41 Million in 2021. Research and Development Expense is likely to rise to about 6.9 M in 2022, whereas Consolidated Income is likely to drop (13.1 M) in 2022.
  
Check Entera Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entera main balance sheet or income statement drivers, such as Cost of Revenue of 366.7 K, Gross Profit of 187.3 K or Operating Expenses of 12.6 M, as well as many exotic indicators such as Asset Turnover of 0.0235, Book Value per Share of 0.93 or Current Ratio of 6.82. Entera financial statements analysis is a perfect complement when working with Entera Bio Valuation or Volatility modules. It can also supplement Entera Bio's financial leverage analysis and stock options assessment as well as various Entera Bio Technical models . Continue to the analysis of Entera Bio Correlation against competitors.

Entera Net Cash Flow from Operations Breakdown

Showing smoothed Net Cash Flow from Operations of Entera Bio with missing and latest data points interpolated. A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.Entera Bio's Net Cash Flow from Operations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entera Bio's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (11.53 M)10 Years Trend
Decreasing
Slightly volatile
   Net Cash Flow from Operations   
Share
       Timeline  

Entera Net Cash Flow from Operations Regression Statistics

Arithmetic Mean(5,741,038)
Coefficient Of Variation(56.40)
Mean Deviation 2,985,893
Median(3,142,000)
Standard Deviation 3,238,229
Range 7,415,000
R-Value(0.87)
R-Squared 0.75
Significance 0.00012778
Slope(720,368)

Entera Net Cash Flow from Operations History

2017-4.5 M
2018-9.8 M
2019-8.9 M
2020-10.6 M
2021-9.1 M
2022-9.8 M

About Entera Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Entera Bio income statement, its balance sheet, and the statement of cash flows. Entera Bio investors use historical funamental indicators, such as Entera Bio's Net Cash Flow from Operations, to determine how well the company is positioned to perform in the future. Although Entera Bio investors may use each financial statement separately, they are all related. The changes in Entera Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Entera Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Entera Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Entera Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Net Cash Flow from Operations-9.1 M-9.8 M
Free Cash Flow-9.1 M-9.8 M
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.

Entera Bio Investors Sentiment

The influence of Entera Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Entera. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Entera Bio Implied Volatility

    
  23.02  
Entera Bio's implied volatility exposes the market's sentiment of Entera Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Entera Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Entera Bio stock will not fluctuate a lot when Entera Bio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Entera Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Entera Bio's short interest history, or implied volatility extrapolated from Entera Bio options trading.

Pair Trading with Entera Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Entera Bio

0.68BBIBrickell Biotech Earnings Call  TomorrowPairCorr

Moving against Entera Bio

0.79CVMCel-Sci Corp Fiscal Year End 28th of December 2022 PairCorr
0.65BLUEBluebird Bio Normal TradingPairCorr
0.57MEIPMei Pharma Fiscal Year End 1st of September 2022 PairCorr
0.54BCTXBriaCell Therapeutics Fiscal Year End 27th of October 2022 PairCorr
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Entera Bio Correlation against competitors. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.